Cargando…

Why we should have more collaboration on HTA in Europe: the example of sofosbuvir

Detalles Bibliográficos
Autores principales:	Schelleman, Hedi, Dupree, Rudy, Kristensen, Finn B, Goettsch, Wim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603626/ http://dx.doi.org/10.1186/2052-3211-8-S1-O13

Ejemplares similares

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

2.G. Workshop: The development of HTA collaboration in Europe: where we are and where we are going
Publicado: (2022)

CONSORT: missing missing data guidelines, the effects on HTA monograph reporting
por: Sylvestre, Yvonne
Publicado: (2011)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

HTA Implementation Roadmap in Central and Eastern European Countries
por: Kaló, Zoltán, et al.
Publicado: (2016)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

Why not integrate ethics in HTA: identification and assessment of the reasons
por: Hofmann, Bjørn
Publicado: (2014)

The completeness of intervention descriptions in published NIHR HTA funded trials: a cross sectional study
por: Douet, Lisa, et al.
Publicado: (2013)

40 years of anorexia nervosa: why we should never give up
por: Hill, Stephanie, et al.
Publicado: (2014)

The development of HTA collaboration at European level and the challenge of the EU regulation
por: Ruether, A, et al.
Publicado: (2022)

Applying Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer
por: Angelis, Aris, et al.
Publicado: (2015)

Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit
por: Halmesmäki, Esa, et al.
Publicado: (2016)

Why and how can HTA support evidence-informed health policymaking?
por: Gutiérrez-Ibarluzea, I, et al.
Publicado: (2022)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials
por: Jones, Ashley, et al.
Publicado: (2013)

Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe
por: Monleón, Clara, et al.
Publicado: (2022)

Why the Army Should Have a Veterinary Corps
Publicado: (1900)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
por: Daubner-Bendes, Rita, et al.
Publicado: (2021)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

Why Registries are Important: The Example of the Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI)
por: Hughes, Richard E., et al.
Publicado: (2020)

Why should we apply ABM for decision analysis for infectious diseases?—An example for dengue interventions
por: Miksch, Florian, et al.
Publicado: (2019)

Why Australia and Indian Researchers Should Collaborate to Advance Wound Management Innovation?
por: Upton, Zee
Publicado: (2013)

The department of startup: why every fortune 500 should have one
por: Lee, Sam
Publicado: (2019)

Why Should DNA Topoisomerase I Have a Scaffold Activity?
por: Di Felice, Francesca, et al.
Publicado: (2021)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective
por: Mycka, J, et al.
Publicado: (2022)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

European Collaboration in Health Technology Assessment (HTA): goals, methods and outcomes with specific focus on medical devices
por: Erdös, Judit, et al.
Publicado: (2019)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

Why workforce health should have a place in UK care reform
por: Shemtob, Lara, et al.
Publicado: (2022)

The Progress of Our School: Has It Been What It Should Have Been? If Not, Why Not?
por: Adams, Edward
Publicado: (1899)

Use of Surrogate end points in HTA
por: Mangiapane, Sandra, et al.
Publicado: (2009)

Ethics in HTA: Examining the "Need for Expansion"
por: Abrishami, Payam, et al.
Publicado: (2017)

Impact of COVID-19 pandemic on HTA
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mahpfqplh3jgvjf57i4ngk0jdv